# Episode 202 - November 6, 2026

Biotech Hangout · 2026-11-06 · 60 min · https://www.youtube.com/watch?v=RSVZg4eK7NM

## Transcript

Brian Skorney

You are listening to Biotech Hangout, a live and unedited weekly discussion of all the latest news in our industry with a group of biotech leaders and experts and, for some inexplicable reason, me, Brian Skorney. With me today are co-hosts Paul Matteis, Yaron Werber, and, as a special guest co-host, Adam Feuerstein. For more information about our hosts and guest speakers or to listen to the most recent episode, please go to biotech hangouts.com.

So everyone, this has been a pretty busy week. XBI is down 3% on the week right now. The S&P is down around 2.5%. It’s the heaviest earnings week of the quarter, at least for me, and we did have a little election here in the U.S. I’m not sure whose idea it was to give me the reins to run point on Hangout today and bring Adam in at some point. I’m hopeful we’re not going to get canceled, but either way, I think we’re going to have a really fun discussion today.

### The Election’s Biotech Impact

Let’s start with something none of us are really fit to opine on, but we’re going to do it anyway: policy. Blue tsunami on Tuesday night. I’m not sure if everyone had heard about this news this week, but the midterm elections led to a pretty big shift in legislative control. Democrats took both the House and Senate, and not by small margins. Polling in recent years has tended to underestimate Republicans, so while there was definitely an overall view that the Democrats were going to take the House and maybe squeeze out a Senate majority, this time polling and even the betting odds seemed to massively underestimate them.

The party wound up flipping 7 seats in the Senate and 42 in the House. The last I checked, 2 Senate races and 29 House races were still uncalled. Some of those flips were pretty surprising. One that could have a big impact on health care and our sector is South Carolina, where Annie Andrews unseated Darlene Graham. I want to talk about Dr. Andrews a little later, too. Texas and Kansas both had Senate seat flips, and Texas even elected a Democratic governor.

There are pretty meaningful implications for a bunch of things relevant to us. We’ve all learned recently that government policy can have a big impact on the macro, which winds up affecting us to a great degree—maybe more than we thought when we started in biotech. There are questions about how the new government might affect fiscal policy, growth, and inflation. Monetary policy has been under more and more government pressure in recent years. Interest rates, both in terms of Fed funds rates and real interest rates, all have major effects on the cost of capital, leading to big shifts in broad-based investing.

Because biotech has such a long investment cycle, there’s a huge impact on NPV from those changes. And because pharma companies can be such cash cows, there may be an inverse effect relative to development-stage biotech.

There’s also going to be a lot of health care-specific policy on the table. The One Big Beautiful Bill enacted numerous changes to cut ACA subsidies and Medicaid. We’ve talked extensively here about the cuts to NIH, CDC, and FDA. There’s ample evidence that many of these newly elected officials have been campaigning to reverse those things.

One of the many interesting things is that a lot of these newly elected legislators are medical doctors: 2 senators and 4 congressmen. Abdul El-Sayed was perhaps part of the most visible Senate election nationally. He got his MD from Columbia, just north of me here in Washington Heights, then a doctorate in public health. He was a professor of epidemiology at Columbia and has had several health administration roles in Michigan.

He’s been an outspoken advocate for Medicare for All, which I think a lot of us in biotech probably don’t love. He’s written about lowering prescription drug costs, which I definitely don’t think a lot of us in biotech love. And he’s been a sharp critic of HHS Secretary RFK Jr., which I think a lot of us in biotech probably do love.

The other MD elected to the Senate is Annie Andrews, who turned a pretty red seat blue. She’s a pediatrician who has practiced since 2009, and health care has been a big part of her platform. She’s outspoken about fully funding Medicaid again, protecting Medicare, and fully funding CDC and NIH. She explicitly condemned RFK Jr. and said, “He’s been my professional arch nemesis for decades, and any other pediatrician in this country would say the same.”

I don’t know about any other pediatrician, but I can attest to being married to one. Pretty much every pediatrician I know feels that way.

The normal gut reaction from both capital markets and pharma is that Democrats are bad for both. We saw volatility all over the map as the election was going on Tuesday night, showing the magnitude of the sweep. Futures were significantly down, but by Wednesday’s open they had reversed, and the market had a big move up. The Dow saw its best performance on a post-midterm-election day in 44 years.

There were even some cracks then, particularly around names with exposure to the data center buildout, another area that a lot of these candidates’ platforms were pushing against. What we saw on Thursday gave it all back and then some. I think we can all attest that it was a really horrific day yesterday.

With all that being said, we’re now brought to the Biotech Hangout brain trust. I’d love to go around the horn and hear everyone’s top reasons to be bullish on biotech with this new government, their top reasons to be bearish, and how they think it nets out. I’ve already spoken a lot, and I need to hear what all the smarter people in the group have to say so I can take the best takeaways for myself.

I’ll round it out with an opinion, but I’d love to hear from my other co-hosts. What are you guys hearing from investors? What are you telling investors about the outlook with this new government?

Paul Matteis

Should I go briefly?

Brian Skorney

Do it.

Speaker 1

Thanks, Skorney. You should have a radio show, dude. That was awesome. Just sit and ramble. I love it. I would listen.

Speaker 2

No, no, we’re going to nominate you to be the host every week from now on.

Paul Matteis

Yeah, that was great. I mean, for health care broadly, I couldn’t agree more with what you’re saying, Brian. Rescuing the credibility of HHS is important. We’ve obviously had some tough times with the FDA. It feels a little bit more stable, but we don’t have a long track record with the new leadership of the agency right now.

Some of the impacts of RFK on our sector are indirect or more specific, like things with vaccines. But having greater stability is important. I want the FDA to get back to a point where we look up to it for its standards and consistency, and it feels like it’s going to take changes on the political side to get us to a more stable place.

For drug stocks, it does feel like this introduces greater risk. The past couple of years have been marked by chatter around MFN and tariffs, with nothing of any consequence. I think a number of us—Skorney, Yaron, and I—cover companies in different specialty indications where they’ve priced way above expectations and launches have crushed it. I’d already been talking to investors who felt like some of the pricing felt a little unsustainable. It seems like if Trump decides to work with this Congress, drug pricing could be a logical area of compromise.

To me, that’s the biggest risk. Maybe the FDA stability issue is more of a longer-term thing, and maybe it’s a good thing for the sector and for society. I don’t know if it becomes more stable in the near term. I’m not sure if this new commissioner gets confirmed or how that all looks. For stocks, there’s probably more downside risk from this kind of stuff in the next year, even if there might be healthier improvements to major institutions over the long term. What does everyone else think? Adam, do you want to go next?

Adam Feuerstein

Oh, you want me to go? Gee. I don’t have a lot to say here other than that I agree with everything. I agree with much of what Brian and Paul said. If I put on my cynical hat, I’d say nothing changes. There’ll be a lot of rhetoric, particularly around drug pricing, but I don’t know. There seemed to be a big effort over the last 2 years, and it amounted to very little, so you sort of have to believe the Democrats can do something more effectively. I don’t know if that’s necessarily going to be true.

Paul, you do bring up a good point: if Trump decides he wants to work with the Democrats, maybe drug pricing is one of those things. But again, my cynical nature says this is D.C., and they’ll manage not to do a lot.

There’ll be a lot of headlines, but at the end of the day it won’t really matter.

Yaron Werber

Yeah, I tend to agree. I think we’re going to be pretty clearly in gridlock for the next 2 years. We’ll need to see exactly how much they try to go after Trump for whatever mishaps one can bring up and discuss, and whether that’s going to come back and bite them in the next election as it did last time is TBD.

The way I’m thinking about it is that the macro is almost more important for biotech than drug pricing. When we talk about macro, I’m talking about interest rates, what’s going to happen with AI regulation, and the view on tech holistically, because if the market’s going to be under pressure, it’s hard to see how biotech is immune. So I think it’s a question of how much collateral damage we’re going to see. If they’re really going to go after AI, whether through regulation or what happens with the data centers, I don’t know that biotech is going to be the beneficiary of the trade, especially if rates stay higher.

There’s a real question about whether biotech was impacted last time because of rates, because it was the delta—the slope of how much rates went up and how quickly—versus just higher for longer. It looks like rates are going to go higher and stay there for an unknown length of time. I think the bull case in biotech is that rates are going to go up with a slower slope now, so we’ll be more immune. So far, if you look at the indices, one of the challenges, as we all know, is that the XBI isn’t just biotech; it’s got some diagnostics in there. The IBB is different, but it definitely looks very different from the overall tech indices right now. So we’re sort of benefiting, but we’ll need to see. Anyway, I think it’s going to be more market-driven, in our view.

Brian Skorney
I do wonder, Yaron and Paul, about Heidi Overton at the FDA—what this means for her and whether that nomination happens or not.

Yaron Werber
Yeah. I kind of feel like no. She’s not all MAHA.

Paul Matteis
I kind of feel like no, too. If you put me on the spot and said I had to give you a prediction, I would say no.

Brian Skorney
You know what? I actually think I’m really happy with Kyle Diamantas. I was a little upset he wasn’t the actual nominee, and I understand maybe he doesn’t even really want the permanent job. Janet Woodcock was interim commissioner for a really long time. I forget, there’s some statutory rule about how long you can have an acting commissioner in place. But I’m happy. I think he’s done a really good job, certainly in contrast to his predecessor. I think the status quo at the FDA feels much more stable right now under him, so I’m happy to have it.

Yaron Werber
I mean, is it stable? I totally agree. I’m not playing devil’s advocate at all, but is it stable because there are just no longer major controversies every 5 minutes, and they’re not putting out policy papers every 2 weeks and then ignoring them?

Adam Feuerstein
Well, it’s definitely stable because the guy running the agency isn’t doing walk-and-talk videos or podcasts. From that perspective, it’s much more stable.

Paul Matteis
Not commenting on programs on CNBC and conflating 2 drugs. Ultimately, we’d have to see more regulatory actions play out over time to understand stability, to Yaron’s point. If Unicycive gets approved or rejected, it’s hard to say it’s any sort of referendum on FDA stability, because this current iteration of the FDA has been a saga across 2 or 3 different leadership teams. But I agree with Brian: the current commissioner seems good. It just sounds like he doesn’t want the job.

We talked to a consultant the other day, just as it relates to what the blue wave could mean. One speculation was—and no one knows—but if you’re an outgoing Republican senator, maybe you went down in this election and were a big supporter of the Trump agenda. Do you really want to confirm this commissioner? How high a priority is that? We’ll also see what’s happening with HHS leadership at the same time. I don’t know. In the backdrop of that, how long is the Senate in session between now and January 20th? Is this even a top priority? I have to wonder if the FDA commissioner situation could drag on with uncertainty for some time.

Brian Skorney
Well, yeah. I guess I’ll wrap things up. We’ve talked a lot, and I want to get into more of the specific stuff, but I think we’re going to hear a lot of noise. We have some loud DSA voices in the Democratic Party, and you’re probably going to hear about Medicare for All. You’re probably going to hear Bernie Sanders pushing to escalate talks of drastically reducing drug prices.

But when I look at what happened, most of these newly elected Democrats in red states are really left of center, right? They got elected by people who are right of center, willing to flip and frustrated with Trump policy. So I’m more optimistic than Adam that things will get done and there’ll be some collaboration. Trump has hinted at it, but no one knows; Trump is very hard to predict. I think what we’ll see are things that aren’t catastrophically bad for the sector and maybe even modestly good. I think a lot of access and new investment will be freed up. So I think it’s a net positive, but we’re in for some noise over the next couple of months. I also agree with Yaron that the macro, interest rates, and spending outside of biotech can have a material impact.

Adam Feuerstein
The industry might do itself a favor by not trying to set record pricing for every drug that gets approved. Maybe throttle it back a little bit. That might be a good idea.

Brian Skorney
Maybe.

Yaron Werber
We’ve been having this conversation for 20 years, right? Keep doing this.

Adam Feuerstein
I know, but it just seems like it’s gotten worse. I don’t know.

Brian Skorney
No, and I didn’t mean to imply that it wasn’t people’s own doing. I think you’re right, Adam. It’s kind of crazy. I think let’s move on from some of the election stuff and get into more specific stuff. There are a lot of juicy things to talk about. It was a dense earnings week, but I don’t think we’re just going to recap earnings here. I think we’re going to have some fun debates on a few things that investors have been fighting about.

### Vertex’s IgAN Label Debate

I’m not going to be the one to introduce this nuanced debate around Vertex’s soon-to-be-approved drug for IgAN, but I’m definitely opinionated on it. I’m looking forward to this discussion with the others, but I’m going to pass it over to our guest speaker today, Adam Feuerstein, to give us the setup.

Adam Feuerstein
Yeah. The setup on this, Brian, is Vertex’s IgA nephropathy drug, povetacicept. We’ll call it POV. The PDUFA date is November 30th, so it’s coming up. I think, as you alluded to in your intro, everyone thinks this is getting approved. There’s very little doubt that this drug is going to get approved. If and when it is approved, it will compete against the Otsuka drug and the Vera drug in IgAN. It’s a very large market. Those 2 drugs are already out there competing, and we’ll have Vertex’s POV coming in to compete.

What’s been kind of interesting over the last couple of weeks is this controversy over a treatment halt that was built into the protocol of Vertex’s phase 3 study. It was something no one knew about until a citizen petition was filed with the FDA. It was filed by a law firm on behalf of an anonymous client, asking the FDA to require monitoring of immunoglobulin levels in the POV label. Apparently, in the protocol, if IgG levels dropped below a certain threshold, there was a requirement that you could temporarily halt the use of POV until those IgG levels returned to normal. I guess we didn’t know about that until it came out in the citizen petition.

Naturally, people asked Vertex, “How many patients in your study had their treatment temporarily interrupted?” Vertex has not provided that answer; they’ve declined to provide it. What Vertex has said is that the most important thing here is infection risk, because if IgG levels go down, patients have a higher risk of infection. Yet if you look at their phase 3 study, the infection risk was the same in the drug arm and the control arm.

Adam Feuerstein
Therefore, there is no infection risk, and Vertex has stuck to that line. They have not provided more detail about whether any patients actually had to have their treatment temporarily halted. That matters because Otsuka’s and Vera’s drugs do not have patient-monitoring requirements in their labels. If that were introduced into the povetacicept label, it would put Vertex at a competitive disadvantage.

So, Brian, what do you think?

Brian Skorney
I love this debate. The first thing to be said is that this mechanism is showing miraculous data. We could get into the nuances of the mechanism, because there are slightly different hypotheses that may have applicability, but let’s just say that targeting B-cell modulation to lower immunoglobulins, including IgA, seems, for the most part, to stop the progression of the disease. Certainly, in the Otsuka data, which includes multiple years and hundreds of patients, it looks that way.

We don’t know all the patient-level data, but the mean eGFR decline in their Phase 3 study is basically zero. It’s actually up a little bit. At ASN last week, we also learned that they have a huge impact on outcomes. I think there was a 98% reduction in composite kidney outcomes. Zero patients on treatment went on to receive a kidney transplant, versus, I think, 5 on placebo.

You interfere with B cells and their ability to make IgA, and this is a miracle treatment for patients with IgA nephropathy. The downside is something we know about well beyond this data. There’s an approved BAFF inhibitor that does something very similar to these drugs, called belimumab. As long as you give this drug, IgG and all the other immunoglobulins go down. You’re basically impairing B-cell function, and B cells make immunoglobulins.

If you make no immunoglobulins, you run serious infectious risk. If you look at the belimumab data, in a different indication, lupus, there’s about a 1-in-10,000 risk of PML. As we all know from our days covering Biogen, that’s a very deadly reactivation of an infection called the JC virus.

There’s some level of inevitability that you will increase infections. Vertex’s argument is, “Yes, we see IgG reductions, as does Otsuka’s sibeprenlimab and Vera’s atacicept, as does anything that is going to suppress B-cell function. But look at the infections—there’s nothing that jumps out in the safety data.” I don’t think that’s a fair argument. It’s a short study. B cells—or IgGs—are declining throughout the entire study, and they’re not getting to a trough. IgA nephropathy is a 20-year disease; these patients are going to be on these drugs for 20 years.

Just because you’re not seeing an increase in infections when you’re reducing B cells or IgG by half of what you’re ultimately going to do, it doesn’t mean that when you get all the way down to zero, there won’t be an infection risk. I do think it’s a little bit of gaming the clinical trial to say, “Our IgG reductions aren’t that bad. We don’t have any cases of hypogammaglobulinemia,” when it’s because the study is designed to monitor IgGs heavily and interrupt treatment when they go below a certain level. Then they can say, “Our IgGs never went below this threshold level of hypogammaglobulinemia.” It’s an on-mechanism effect, so if you stop exposure to the mechanism, of course it’s going to happen.

These drugs are great. The benefit is more than worth the risk. It takes some thoughtfulness about monitoring, treatment holidays, and how to think about infection risk versus who you treat. Ultimately, I think there are better ways to do this. You guys are going to make fun of me for being a big Biohaven bull here, but this is a sort of single-immunoglobulin issue. It’s Gd-IgA1. If you can just target Gd-IgA1, you’re not going to have any of these infectious risks. No one’s going to have hypogammaglobulinemia, and no one’s going to see IgG reductions.

It’s not just Biohaven starting a pivotal study with its Gd-IgA1 reducer; argenx also has an IgA sweeper, and that data looks really good. I think we’re seeing more and more targeted, selective therapy. Vertex is going to be third to launch. They have much less data than Otsuka, which, for this group of mechanisms, I think is really the ideal drug.

Speaker 1

Brian, what would you do with the label if you were the FDA on this monitoring issue? As an analyst covering this, I feel like it’s a little bit unknowable to guess how this plays out. My gut is that they’re not going to get the monitoring requirement, but I really don’t know.

Brian Skorney

I don’t think the FDA will require it. Again, Vertex is gaming the system a little bit here, but this is on-mechanism. It happens with sibeprenlimab and atacicept. We can see there’s monitoring when we look at the New England Journal articles, and we have the IgG data for everyone. So it is monitored, but they didn’t require monitoring on the label here.

I think it’s sort of: you do it for the class, or you don’t do it for the class. So far, the FDA has not done it for the class. There may arguably be a little more evidence that povetacicept could lower IgGs more. I think they had 3 cases of hypogammaglobulinemia in the Phase 1 study, but these are all small numbers and hard to compare.

I think the FDA only puts some sort of IgG-monitoring mechanism on the label if they’re going to do it for all of these B-cell modulators. The bigger issue is what nephrologists do. I don’t know what you guys are hearing from ASN, but nephrologists are aware of this. No one’s saying, “Oh, this lowers IgGs? I never knew that,” just because this protocol came out. They know this is going to take more attention in terms of managing these patients down the road.

You also have to account for the fact that Vertex has been asked about the label, both at the ASN meeting and on the earnings call. Reshma has been very clear that they feel they’re going to get essentially the same label as everyone else, without patient monitoring. I tend to believe that. It would be odd for them to be as aggressive as they’ve been if they didn’t know what was going on behind the scenes, even though they don’t want to answer that question that keeps getting asked.

The other thing, stepping back, is that what I find fascinating about all this is that this is going to be the first time since hepatitis C that Vertex has to compete in a market. They obviously don’t compete now with cystic fibrosis, and—

Well, I mean, yeah. If you want to say pain and—

Speaker 1

Yeah, and how miserably have they done with pain? That’s been a total disaster from a commercial perspective, as has Casgevy in sickle cell. That’s a financial black hole they keep pouring money into.

Speaker 2

And so, to me, that’s kind of interesting. Vertex has never really had to compete; they really know how to work for their supper, so to speak. Here they have 2 very formidable competitors with drugs that seem to help patients quite a bit. There’s not a lot of daylight between these 3 drugs. They’re coming in third to market, as you said, Brian, with less data because of the follow-up and everything. It’ll be very interesting to see how they compare.

Brian Skorney

I would also say it’s not a small difference that Vertex isn’t going to have eGFR-decline data or outcomes data for about 2 years. They’re going to get accelerated approval, while Otsuka and Vera get full approval based on actual kidney-function outcomes. Vertex is going to be marketing proteinuria, which can be a great marker, but there’s a big difference between kidney outcomes and a biomarker.

### Revolution’s Explosive Launch

Speaker 2

Moving on, one of the biggest stories in the sector over the last year or 2 has been Revolution Medicines and its drug, which is approved and launched for pancreatic adenocarcinoma. Adam, you’ve been following this closely, and I know that with any new launch there’s a bull-bear debate about what the initial sales numbers will look like. Give us the setup going into the first numbers from this launch.

Adam Feuerstein

Right. We’re getting the first indication of Q3 sales for what would amount to about 5 weeks of sales, given the late-August approval. There was a lot of speculation and a lot of expectations. Obviously, this drug is providing great benefit to pancreatic cancer patients, and there’s a lot of hype and excitement about it. What was that first print going to look like? Buy-side whisper numbers were in the $80 million to $100 million range.

Speaker 1

And they blew that out of the water, right? I mean, $198 million in 5 weeks. Again, they blew the doors off pretty much every expectation. It was a phenomenal start to this launch, which looks like it might be one of the strongest oncology drug launches of all time.

Speaker 2

Yeah. It was very shocking, and obviously there’s a big debate about valuation. This is a very big market cap for a single drug launch. But the data has been really great, and by all estimates, this was way above expectations.

One of the favorite hedge fund sayings is “short the launch.” Expectations always get ahead of themselves. What are your thoughts on the stock’s action in the aftermath? Anyone have any color?

Paul Matteis

Is the fear that this is going to flatten out in 3 quarters, and then what do you do until you get the label expansion into frontline or other indications? I don’t cover RevMed, but I’ve heard the bear case: it’s already expensive, it would be a huge takeout, and Yaron and I have talked about this in other calls.

Look at how Alumis and Insmed played out, where the buy side got to the numbers ahead of the sell side. People say consensus is low, but eventually the beats aren’t enough. Again, this isn’t a call on RevMed’s stock. It could still be a total monster, but I think that’s the historical comparison the bears are worried about.

Yaron Werber

Yeah, I hear the same thing, Paul. And again, Brian, you cut out, so I didn’t hear everything you said after I had spoken. But there was a certain amount of tailwind in that first 5 weeks because they had so many patients on the EAP and a lot of pent-up demand, which they won’t have in Q4 and moving forward.

The thing I hear most is that this is just a very expensive company now, a very expensive stock. So execution has to be perfect.

### Drug Safety Controversies

Speaker 2

All right, next up, Adam and I have both been following the story of a drug called Vykat XR since it was developed by a little company called Soleno Therapeutics. Adam, you’ve been writing prolifically about it since those early days, so I’m going to let you once again set this one up.

Adam Feuerstein

I think the debate here is pretty simple. This is a drug for Prader-Willi syndrome, which is a terrible disease. Patients have an insatiable obsession and desire to eat. They overeat, they’re obese, and they suffer from all the conditions that come with that.

Since this drug was approved about a year and a half ago, there have now been 8 deaths of patients who have been prescribed Vykat. Well over 100 patients have been hospitalized. This is all coming from the FDA’s AEMS safety database, which used to be called FAERS. I FOIA’d the death reports for my last story.

The case reports on the 7 deaths are pretty horrible. These are patients’ deaths, mainly involving hypoglycemia or some form of edema or swelling that contributed to the deaths. The issue, or the controversy, is that these are known comorbidities of Prader-Willi syndrome, particularly edema and swelling. They’re also known risks of Vykat; the label has safety warnings that the drug causes swelling.

How much is attributable to the drug, and how much to the comorbidities of the disease? What impact will all of this have on the drug’s uptake?

Brian Skorney

Yeah, I think both Paul and I cover Neurocrine, which purchased Soleno and now markets Vykat. I certainly covered Soleno, and I don’t know that I disagree with you about the risk here. Is causality going to be established, or has it been established?

The other side of the coin is that the data Vykat was approved on wasn’t traditional, knock-it-out-of-the-park, home-run data. It was approved on a randomized withdrawal study after the primary analysis wasn’t successful.

We see this a lot in different diseases, and I think we’re going to talk about something related to this in a few minutes. We wind up in a very gray area: drugs hurt people. Any powerful drug is going to cause some safety issue at some rate, sometimes even death. Even very safe drugs do that every now and then.

When we get into this gray area, where we think there’s efficacy but not to the extent we might see with a true appetite and obesity drug, it becomes a big debate in the orphan sector. It’ll be interesting to see how this plays out. This is obviously a really terrible disease, one of the worst I’ve ever come across, but I hear the issues here.

The question is whether they can maintain sales at all. This has negatively impacted Neurocrine as a stock so many times. It’s overshot even the price they paid for Soleno. At this point, generating any sort of cash flow from the deal might be a positive for the stock. The question is whether this is going to get—

Yaron Werber

The company is talking to the FDA. There seems to be some consideration for label changes or potentially a REMS, or something that would help mitigate some of these risks.

Speaker 2

Adam, did you listen to their call?

Adam Feuerstein

I did.

Speaker 2

Because I thought the Neurocrine CMO was super credible, and I thought she made a comment that they felt the label appropriately depicts the risk. You can say it’s the company saying that, but I felt like I heard that as: they don’t think the label’s going to change, but they are going to do this study in a high-risk population to look at that.

Adam Feuerstein

I think that’s a little bit of talking out of both sides. They say the label is fine, but they’re doing this study. I don’t think they would be doing the study if everything were fine.

Speaker 4

Or if the FDA didn’t want it.

Adam Feuerstein

I think they’re looking at this because you might be able to tease out a population of patients where this risk is much higher. Not to cross diseases, but if you think about Duchenne, ambulatory and non-ambulatory patients are a little different. With Elevidys, they ultimately took it off the market for non-ambulatory patients.

Is there a patient characteristic or risk factor that might make this drug unsuitable for some patients versus others?

Speaker 4

Makes sense.

Speaker 2

Okay. And to keep it in the controversy, Madrigal reported this week, but the print may have been a little overshadowed by a whistleblower lawsuit. What’s the background here?

Adam Feuerstein

This one kind of came out of nowhere. The whistleblower lawsuit was actually filed back in early October, but it didn’t really get out there until Madrigal filed its 10-Q and disclosed the lawsuit.

A former executive of the company is claiming that drug-induced liver injuries and drug toxicity are tied to resmetirom. It was part of his job to look at pharmacovigilance. He identified these concerns in both the clinical trials and the postmarketing safety database, brought them to the attention of top management at Madrigal, and they basically told him to stop looking at the data. Then they demoted him, and he says he was forced to resign.

These are all allegations in the lawsuit, so it’s hard to know what to make of it. Is this a guy looking to get paid by the company? Are his claims legitimate? Obviously, the company is at a disadvantage because it hasn’t formally responded to the lawsuit yet.

Speaker 1
And we’ve gotten statements from them saying they’re obviously going to defend themselves vigorously. I guess I don’t know how you guys feel about it. I’m curious: is this just an overhang on Madrigal for a little while until it gets cleared up?

Speaker 2
I’m not too close to it. I don’t know, Paul. You’re on.

Paul Matteis
I’m not too close to it either, but what could be the ultimate consequences of this?

Speaker 3
Well, I think that’s a good point. I think the point about drugs on the market—

Speaker 1
The point the company makes—and it’s a good point—is that this drug has been approved for about 4 years. It’s now been prescribed to about 56,000 patients with MASH who have used Rezdiffra, and there’s no indication that the drug is tied to drug-induced liver injury. They just haven’t seen that. If this were an issue, if this were a problem, it would have surfaced already, and it hasn’t. That’s a persuasive argument.

I do wonder, how come we haven’t heard about this before? I was talking to some investors about this after the lawsuit came out, including one who’s a pretty significant shareholder. Their point was that we do doctor calls all the time, particularly with competition coming, and we talk to treating physicians in MASH. None of these physicians, who treat tons and tons of patients, have ever mentioned liver toxicity issues to the extent this guy is alleging. That’s very odd to them.

Speaker 2
Yeah. Go ahead.

Speaker 3
I was just going to say, in a world where it usually takes a lot to have a real, tangible impact on a drug that’s on the market, it’s hard to see what the path is here. We talk about situations where a drug on the market doesn’t work in its confirmatory trial, and it’s still complicated to know whether it’s going to get pulled. Or look at the Vykat XR situation, where there are patient deaths and we’re debating whether there are implications. In the context of this drug being so widely used, it’s harder to see how this meaningfully changes things. At least for me, it’s hard to see the path.

I think you mentioned it with FCS, too. You wind up in this dynamic when a drug is approved: how do you really establish causality? Part of the problem with MASH is that you’re talking about a progressive liver disease, so you can’t evaluate for DILI the way you traditionally can for a nonprogressive liver disease. These patients are generally going to continue progressing. Madrigal’s data looks good, so hopefully it’s improving more patients than are getting worse, but you’re still going to have patients progressing to F4 cirrhosis and liver transplant in the experience. How do you attribute that to the disease versus the drug?

I know, having massive scars from covering Intercept, that was always kind of the issue when you had control data, too. Here, you’re in a situation where you don’t really have control. It’s probably not liver toxic, given the number of patients who’ve had it, but disproving a negative in the commercial setting is very hard. Maybe moving on. Paul, I think you have a couple of things this week worth discussing. Let’s start with mushrooms.

Paul Matteis
Yeah. Please. Let’s start with mushrooms. Let’s finish with mushrooms. This is a really crazy situation. I don’t know how closely everyone here has been following it, but we’ve talked about Compass Pathways and psychedelics on this show. Compass is close to completing its NDA submission, has a Commissioner’s voucher, and may be able to get approval in the next handful of months for COMP360.

There’s been a nonprofit called the Usona Institute that’s also developing synthetic psilocybin for depression. They’ve done major depressive disorder; Compass has done treatment-resistant depression. The main difference is the severity of the population, but it’s a similar concept. Usona is very stealthy, from my perspective. They’ve completed Phase 2 and Phase 3. The Phase 3 trial completed a year ago, but the data isn’t public. Compass has said they’ve talked to the study’s PIs, who don’t know the data, which I think is a little atypical.

The perception was that this could come to market at some point. Usona has an admirable mission of trying to make this broadly available, or available to people who otherwise wouldn’t be able to get a psychedelic because of cost or access. No disparagement of the mission whatsoever. We just didn’t really know what the data was, and we still don’t know if the study was technically positive. I think the general view in psychedelics is that you’d need a second Phase 3 for approval.

It was a big surprise this week when a seemingly credible psychedelics reporter, someone who writes thoughtfully about the space, reported that Usona had completed an NDA filing for its product. Again, that’s super surprising because they have less data than Compass, and we haven’t seen the Phase 3 data. This creates a whole host of questions for Compass in the psychedelic space. The biggest question is what the commercial implications are for Compass if a nonprofit gets psilocybin approved at the same time, or maybe even first, and sets the price really low. Does that essentially undermine the Compass business model?

The other fact I should mention is that the head of CDER used to work at the Usona Institute, not that long ago. I’m not trying to imply anything, because we don’t know if this person has recused himself or whether any of this has anything to do with it. But it’s quite a coincidence, if it’s just a coincidence, that they’re filing under what seems like an expedited path against the backdrop of that FDA connection. It leaves all these open questions.

We spent time talking to the Compass team, and one interesting thing about all these psychedelics—and this has historically been a bear case for the space, but it might conversely be the reason Compass can preserve a real commercial model—is that the supply chain and use of these products are complicated. You need a REMS, a specialty pharmacy, and monitoring at these clinics. Monitoring costs money and effort, so the clinics need to be able to make money off these products in order to use them.

You could see a situation where Usona’s product is in certain channels and not others, maybe with the VA or something like that, while Compass, because its indication is treatment-resistant depression, continues to have this specialty model at interventional sites. This really threw investors a curveball this week. Is anyone else following this or have other thoughts?

Speaker 2
Not that closely. It’s been interesting to watch the psychedelic space move both alongside advances in regulation and advances in decriminalization. I always wonder whether there’s a meeting point where high-priced drugs are just freely available. We have examples in epilepsy where cannabidiol is used and works very well, but a lot of the initial or anecdotal evidence is just from using CBD.

I don’t know where everyone else lives, but there are gummies on every street corner. You see the same thing with ketamine clinics, while Johnson & Johnson does very well selling esketamine. You see the push for psilocybin approvals, but mushrooms seem almost as freely available in corner smoke shops as THC at this point. I find the whole thing fascinating, because these drugs do work for people in many respects, but we’re also steadily moving toward a much freer decriminalization process.

Paul Matteis
I think the CBD analogy is a good one. When push comes to shove, with a serious disease, people tend to want a product they can rely on, knowing exactly what it is and that it’s given by a health care professional. In epilepsy, there are drug-drug interactions, and I feel like there will be a brand market in controlled settings regardless of whether people are eating mushroom chocolates for fun.

These launches are a little bit of a “show me” story. It’s a complicated model to execute. For Compass, the implications of the Usona situation are much closer to home. Investors can say, “Could payers just say, ‘Try the cheaper one first’?” I think this is a complicated market. If these were small molecules that were unscheduled, that would be a very, very big risk.

Speaker 1
For the other psychedelics that have different mechanisms or modalities, like LSD or 5-MeO-DMT, this seems like it would probably have little impact.

Speaker 2  
Yeah, for sure. I don’t want to bring down everyone’s trip going into the weekend, but there’s another story this week that’s maybe a little bit similar to the Vicat story in gene therapy. Zolgensma has had a tough run of it, but it’s been one of the shining stars in gene therapy. So, Paul, I’ll kick it back to you. What did we learn this week about Zolgensma? What are your takeaways?

Paul Matteis  
I’ll be brief, because we have a few other topics. Essentially, a few different media outlets reported a handful of tumor cases in the postmarketing setting among patients who received Zolgensma. I don’t know the veracity of these different posts or reports, but a parent of a patient had talked about how Zolgensma had been linked to tumors and Novartis hadn’t provided all the information, or things like that. Again, I don’t know how real that is, but multiple articles covered the topic.

One notable detail reported here is that a couple of the tumor cases showed evidence of vector integration. That has always been the theoretical risk with AAV: DNA damage, carcinogenicity, or things like that. In the context of SMA, especially types 1 and 2, the disease is so severe that it’s hard to believe a therapy like Zolgensma has significantly changed the risk-benefit profile. At least, I’d say the risk-benefit still looks favorable. I’m not saying the risk hasn’t changed, but there are other treatments. Spinraza is still such an unbelievable drug. The fact that it’s given intrathecally and has remained resilient alongside a one-time gene therapy and an oral medication really tells you what patients and physicians think about it.

For the rest of the gene therapy space, I’ve always had a hard time getting excited about a program for a disease that has other good therapeutic alternatives or doesn’t carry significant morbidity or mortality. We’ve seen other safety issues emerge postmarketing, like liver injury and other issues that can cause death. To me, this reaffirms that AAV currently feels like a rare disease modality. More broadly, developing elsewhere is at your own peril.

Speaker 3  
Yeah, that’s a good rundown. We have a couple of data previews and data lookbacks. I’m going to pass it over to Yaron. I’d love to hear your takeaways from the key ASH abstracts released this week, as well as your thoughts on the Novartis data from its failed Lp(a) program and what that means for the space.

Yaron Werber  
Maybe just to pause on the last point: there are actually 2 recent approvals from Ultragenyx. One is for GSD1a, a disease that requires cornstarch throughout the day because patients can otherwise crash from hypoglycemia. That’s called Glycosade, and it’s just launching. The other is for MPS IIIA, a fairly serious neurodevelopmental disorder with significant unmet need. That’s called UX111. You’d think that one will launch well, and then they’ll be filing for OTC deficiency soon. Of course, there are drugs for that, too. There are going to be 3 more AAV8s and AAV9s coming to market, so we’ll continue to follow that.

Let’s do rapid fire. We’ll start with Lp(a). The AHA presentation is tomorrow morning at 8:45 a.m., so if you’re running or walking the dog, you can tune in. We know the drug is pelacarsen, from Ionis and Novartis, and that program has now failed, so it’s very unlikely to go anywhere else. What we’ll all be looking for is whether there were any subsets that might be more amenable to therapy. It looks like the drug really didn’t have any material benefit at all. These are patients who, as we’ve discussed before, were very well controlled on LDL and on other risk factors, including hypertension.

Companies in the space like Amgen, Lilly, and AstraZeneca, which are conducting major studies, will be looking for subsets that might benefit from therapy, or whether this really needs to be developed as primary prevention. Amgen has said that, based on these data, there are a couple of things they might change in their studies, but that’s still very much to be determined. Recall that the original data suggested—and we’ve covered this—that Lp(a) should be a modifiable genetic risk driver of disease. As more data have emerged, though, the more recent evidence suggests it’s probably much less of a driver when patients are otherwise very well controlled. That’s what we’ll be looking for tomorrow: whether there’s any correlation between underlying LDL levels and risk, versus Lp(a).

While we’re still on Amgen, its Sjögren’s data are coming next Wednesday at 8:45 a.m. at ACR. That’s the late breaker for dazodalibep in systemic disease. The data were really strong, much better than the ianalumab data, which are in front of the agency through Novartis and could potentially get approval by the end of this year. The ianalumab data had 2 Phase 3 studies that needed to be pulled together to hit statistical significance in systemic disease. Dazodalibep hit it out of the ballpark in Phase 3, mirroring Phase 2, and importantly showed benefit on symptoms as well.

The 24-week data hit both the primary and secondary endpoints. The 12-week data hit the primary endpoint, I think, and showed trends on symptoms only. The next study, coming by the end of the year, is in patients with symptomatic disease, which is about two-thirds to 75% of patients. That’s a big deal, and we’ll all be looking at the ACR data for a hint about those upcoming results, which we’re fairly optimistic about.

Amgen also continues to beat numbers. It has a lot of pipeline activity and a lot coming next year. It enrolled all of its MariTide studies really quickly and has now launched a pen formulation in a clinical study, with data expected by June of next year. Assuming success, it will probably file in the second half of next year with the pen, and it’s already doing switching studies from other GLP-1s. Lots going on with Amgen; it was a beat and raise.

BeOne also reported another huge beat and raise yesterday for Brukinsa, the leading CLL drug. Most importantly, BeOne has a BTK degrader and will be first in class. It has now spoken with the FDA and said the Phase 2 was positive. Because it’s first in class, the company will be doing more follow-up to assess durability. It specifically said this isn’t safety-related. We think the filing, which was hoped for late this year, is now moving to the middle of next year. We believe the FDA wants to see a minimum amount of follow-up across all patients and patient subsets, not just a median amount of follow-up.

That probably has to do with the plan to include patients who failed Jaypirca, Lilly’s latest approved BTK inhibitor. BeOne is doing a Phase 3 head-to-head study against that drug, and it’s going very well. They absolutely believe, and we agree, that they’ll be able to show superiority head-to-head. But because they want a label in the refractory setting for patients who failed Lilly’s drug, the FDA probably said those patients are newer in the study, so it wants more follow-up. That’s pushed the filing to the middle of next year, but BeOne is affirming that it could file. A lot is going on with BeOne.

We’ve already covered the Revolution Medicines collaboration and its impact on Tango. On their call yesterday, they reiterated that they don’t expect a drug-drug interaction between RMC-6236, the Revolution Medicines drug, and their own PRMT5 inhibitor. Recall that Tango does have a drug-drug interaction, and that’s why we believe Revolution Medicines ultimately did the formal collaboration with BeOne for that.

Finally, I know we’re doing rapid fire, but the ASH abstracts came out, and what’s really interesting is how tough this could be for Legend and the impact it may face from Gilead’s anito-cel. The anito-cel abstract came out. Remember, they’re in front of the FDA, and the PDUFA date is December 23rd.

Yaron Werber

Anito-cel doesn’t have the same toxicity that Legend has. We’re all waiting to hear the efficacy, so the abstract really didn’t have a lot of new efficacy data from Gilead. We’ll probably get that updated at ASH. I think it’s expected that the Gilead product won’t be quite as effective, but will be a lot safer.

What was new from Legend is that they’re showing they can do prophylaxis by giving a lot of steroids and, as a result, reduce the parkinsonism risk from 4%–6% to 1.25%. There’s still a risk, but the other updated element was a little more data for their in vivo CAR-T for lymphoma, with updated data from EHA midyear. Now, essentially everyone has a 100% response rate, and responses are fairly durable, up to 5 months. The data so far look very interesting. In terms of safety, it’s fairly clean, with much higher response rates so far than ex vivo CAR-T, like Breyanzi from Bristol or Yescarta from Gilead. So in vivo CAR-T looks fairly promising. There’s a lot to look forward to at ASH.

Speaker 2

Yeah, I think the most interesting thing about the ASH abstract was that, after all these years, it was just a one-minute takeaway at the end of this discussion—how little there wound up being from ASH abstracts this year, and how busy we were talking about other stuff. Well, with that, we’re out of time. This was great.
